Your email has been successfully added to our mailing list.

×
0.012589928057554 0.012589928057554 0.012589928057554 0.012589928057554 0.00143884892086347 1.59744320089951E-16 -0.00899280575539549 -0.00899280575539549
Stock impact report

SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SELLAS Life Sciences Group, Inc. (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
Company Research Source: GlobeNewswire
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS) today announced that data from the Company’s ongoing Phase 1/2 study of galinpepimut-S (GPS) in combination with Bristol Myers Squibb’s nivolumab in patients with Wilms Tumor 1 + ovarian cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1 - 5, 2018 in Chicago, Illinois.  Additionally, following the positive outcome in triple negative breast cancer patients (TNBC) from the Phase 2b trial for NeuVax, SELLAS will be conducting clinical and regulatory advisory board meetings at ASCO based on the independent Data Safety Monitoring Board recommendation to expeditiously seek regulatory guidance by the FDA for the development of NeuVax in TNBC. Clinical and immunological data from the ongoing Phase 1/2 GPS plus nivolumab trial evaluating GPS in patients with recurrent WT1+ ovarian cancer in second or greater clinical remission Show less Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SLS alerts

from News Quantified
Opt-in for
SLS alerts

from News Quantified